Continuous subcutaneous insulin infusion (CSII) is an effective tool to improve type 1 diabetes mellitus (T1DM) control, although many patients remain with hemoglobin A1c (HbA1c) levels >7% [3–6]. The gene discussed is INS; the disease is type 1 diabetes mellitus.